Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0262471 (ENT)
 5,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tumour markers are often circulating tumour-associated indicators of tumour development. As such they are not suitable for tumour screening and localization, but valuable as adjuncts for medical follow-up care of tumour patients, where their serum level alterations may anticipate the clinical detection of tumour behaviour by a lead time of 1 to 6 months before other methods. The following tumour may be controlled by established markers: endocrine tumours by NSE, calcitonin, parathormone, 5-HIAA, catecholamines/metabolites etc.; head-neck tumours: SCC, CEA; thyroid carcinoma: TG, calcitonin; lung cancer: CEA, NSE, SCC; liver cancer: AFP (PLC), CA 19-9 (cholangiocell.), CEA (secondary): biliary tract and pancreatic cancer: CA 19-9; colorectal carcinoma: CEA, CA 19-9; squamous cell carcinoma (ENT, oesophagus, anal): SCC; breast cancer: CEA and CA 15-3; ovarian cancer: CA 125 (epithelial), CA 19-9 (mucinous); germ cell tumours (ovary including trophoblastic tumours/testes): AFP and HCG; prostatic cancer: PAP and PSA; bladder cancer: TPA.
 ...
PMID:[Clinical relevance of tumor markers]. 267 6

A group of 54 patients with previously untreated ENT malignancies were studied and findings regarding five markers generally associated with cancers (CEA, SCC, TPA, CA 50 and ferritin) are presented. The specificity of these markers always proved to be greater than 95% while their sensitivity ranged from 13% to 43%, reaching 72% as a combination of all five markers. The results obtained during follow-up on 21 randomized patients was not satisfactory due to poor sensitivity. In the opinion of the authors, the five markers assayed appear to have no distinct function in monitoring ENT cancers. The sole exception to this is SCC which presents a moderate correlation (60%) with tumor growth.
 ...
PMID:[Prognostic value of tumor markers in the follow up of malignant neoplasms of the head and neck]. 269 47